ijms-logo

Journal Browser

Journal Browser

Editorial Board Members’ Collection Series: "Exploring Molecular Mechanisms in Cancer Biology"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 20 January 2025 | Viewed by 2695

Special Issue Editors


E-Mail Website
Guest Editor
BiOSSE (Biology of Organisms: Stress, Health, Environment), UFR Sciences et Techniques, Le Mans Université, CEDEX 9, F-72085 Le Mans, France
Interests: cancer cell biology; DNA repair; transposable elements; bioactive molecules; gene expression; stress response; microalgae
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Institute of Endocrinology and Experimental Oncology, IEOS CNR, Via Pansini 5, 80131 Naples, Italy
Interests: mevalonate pathway; prenylation proteins; cannabinoid and cancer; cell cycle; cancer-related biochemical pathways; cell proliferation; cell signaling; breast cancer; glioblastoma multiforme
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Exploring the molecular mechanisms underlying the formation and progression of cancerous tumors is essential to the development of new strategies for the prevention, diagnosis, and treatment of cancer.

One of the main characteristics of cancer is the uncontrolled proliferation of cells, which can be caused by alterations in the mechanisms that regulate the cell cycle and control cell division and growth. Genetic mutations can disrupt these regulatory mechanisms, allowing cancer cells to divide aberrantly and form tumors. Exploring the molecular mechanisms involved in these genetic mutations can help us to identify the genes responsible for cancer progression and understand how they contribute to tumor formation. In addition to genetic mutations, other molecular mechanisms may also contribute to cancer progression. For example, epigenetic modifications, which do not alter the DNA sequence but affect gene expression, may play an important role in regulating the activity of the genes involved in cell proliferation.

In addition, certain specific proteins may be produced in excess or abnormally in cancer cells, which may favour their proliferation and survival. Identifying these proteins and their mechanisms of action may provide targets for the development of new cancer treatments. The exploration of molecular mechanisms in cancer biology also includes the study of the immune response against cancer cells, the interplay between a tumor and its microenvironment, angiogenesis, increased metabolism, invasion and metastasis processes, the acquisition of resistance, etc.

In short, the exploration of molecular mechanisms in cancer biology plays an essential role in our understanding of the formation and progression of cancerous tumors. It enables new therapeutic targets to be discovered and more effective approaches to cancer prevention and treatment to be developed.

Prof. Dr. Benoît Chénais
Dr. Chiara Laezza
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • angiogenesis
  • cancer biomarkers
  • cancer therapy
  • epigenetics
  • genetics
  • immune response
  • metabolism
  • metastasis
  • mutation
  • resistance
  • tumor microenvironment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 3388 KiB  
Article
Cordycepin Enhances the Therapeutic Efficacy of Doxorubicin in Treating Triple-Negative Breast Cancer
by Haichen Huang, Xiaomin Li, Wenya Wu, Chengyi Liu, Yunhe Shao, Xiaoping Wu and Junsheng Fu
Int. J. Mol. Sci. 2024, 25(13), 7077; https://doi.org/10.3390/ijms25137077 - 27 Jun 2024
Viewed by 1555
Abstract
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with high mortality and poor prognosis. Meanwhile, doxorubicin, a chemotherapeutic agent for triple-negative breast cancer, has poor sensitivity. The objective of this study was to examine the effect of cordycepin on doxorubicin sensitivity [...] Read more.
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with high mortality and poor prognosis. Meanwhile, doxorubicin, a chemotherapeutic agent for triple-negative breast cancer, has poor sensitivity. The objective of this study was to examine the effect of cordycepin on doxorubicin sensitivity and efficacy in the TNBC xenograft model and explore the relevant molecular pathways. The combination of the drugs in nude mice carrying MDA-MB-231 xenografts significantly reduced the volume, size, and weight of xenografts and improved the tumor inhibition rate. The drug combination was significantly more effective than cordycepin or doxorubicin alone, reflecting the fact that cordycepin enhanced the anti-tumor effects of doxorubicin in MDA-MB-231 xenografts. At the same time, the monitoring of several biological parameters failed to detect any obvious side effects associated with this treatment. After predicting the importance of the TNF pathway in inhibiting tumor growth using network pharmacology methods, we verified the expression of TNF pathway targets via immunohistochemistry and quantitative PCR. Furthermore, a TNF-α inhibitor was able to abrogate the beneficial effects of cordycepin and doxorubicin treatment in MDA-MB-231 cells. This clearly indicates the role of TNF-α, or related molecules, in mediating the therapeutic benefits of the combined treatment in animals carrying TNBC xenografts. The observations reported here may present a new direction for the clinical treatment of TNBC. Full article
Show Figures

Figure 1

Review

Jump to: Research

24 pages, 2051 KiB  
Review
Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets
by Urmila Sehrawat
Int. J. Mol. Sci. 2024, 25(19), 10835; https://doi.org/10.3390/ijms251910835 - 9 Oct 2024
Viewed by 671
Abstract
Eukaryotic protein translation has slowly gained the scientific community’s attention for its advanced and powerful therapeutic potential. However, recent technical developments in studying ribosomes and global translation have revolutionized our understanding of this complex multistep process. These developments have improved and deepened the [...] Read more.
Eukaryotic protein translation has slowly gained the scientific community’s attention for its advanced and powerful therapeutic potential. However, recent technical developments in studying ribosomes and global translation have revolutionized our understanding of this complex multistep process. These developments have improved and deepened the current knowledge of mRNA translation, sparking excitement and new possibilities in this field. Translation factors are crucial for maintaining protein synthesis homeostasis. Since actively proliferating cancer cells depend on protein synthesis, dysregulated protein translation is central to tumorigenesis. Translation factors and their abnormal expressions directly affect multiple oncogenes and tumor suppressors. Recently, small molecules have been used to target translation factors, resulting in translation inhibition in a gene-specific manner, opening the door for developing translation inhibitors that can lead to novel chemotherapeutic drugs for treating multiple cancer types caused by dysregulated translation machinery. This review comprehensively summarizes the involvement of translation factors in tumor progression and oncogenesis. Also, it sheds light on the evolution of translation factors as novel drug targets for developing future therapeutic drugs for treating cancer. Full article
Show Figures

Figure 1

Back to TopTop